FMP374
Treatment-Resistant Depression (TRD)
PreclinicalActive
Key Facts
About FundaMental Pharma
FundaMental Pharma is a German biotech targeting a major unmet need in treatment-resistant depression (TRD) with a novel, dual-acting NMDA receptor modulator. Its clinical candidate, FMP374, is designed for at-home oral dosing, aiming to overcome the safety and supervision limitations of the current standard, esketamine. The company, built on foundational research published in Science, has a deep CNS-focused team and plans an accelerated 3.5-year path to Phase 2a proof-of-concept. With a clinically validated target and a de-risked development pathway, it represents a promising, late-preclinical asset in the neuropsychiatry space.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression (TRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| CYC-126 | Cyclerion Therapeutics | Phase 1 |
| DOT | Motif Neurotech | Pre-clinical |
| R-107 | Tasman Therapeutics | Phase 3 |
| GH001 | GH Research | Phase 2b/3 |
| COMP360 Psilocybin Therapy | Compass Pathways | Phase 3 |
| Ketamir-2 (Ketamir) | MIRA Pharmaceuticals | Phase 1 |